Mogrify Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$10.2M
- Investors
-
13
Mogrify General Information
Description
Developer of a cellular technology designed to enhance patient care through the development of a novel class of in vivo reprogramming therapies. The company's technology addresses indications in the fields of ophthalmology, otology, and metabolic and other degenerative diseases, uses its proprietary platform technology to direct cell reprogramming and systematically generate functional cell types for disease treatment, enabling researchers to address the issues of efficacy, safety, and scalability which are associated with cell therapy development and manufacturing.
Contact Information
Website
www.mogrify.co.ukCorporate Office
- 25 Cambridge Science Park
- Milton Road, Milton
- Cambridge CB4 0FW
- England, United Kingdom
Corporate Office
- 25 Cambridge Science Park
- Milton Road, Milton
- Cambridge CB4 0FW
- England, United Kingdom
Mogrify Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series A) | 05-Sep-2023 | $10.2M | Completed | Startup | ||
| 7. Later Stage VC (Series A) | 04-May-2021 | Completed | Startup | |||
| 6. Grant | 28-Jan-2020 | Completed | Startup | |||
| 5. Early Stage VC (Series A) | 14-Oct-2019 | Completed | Startup | |||
| 4. Grant | 18-Mar-2019 | Completed | Startup | |||
| 3. Seed Round | 20-Feb-2019 | Completed | Startup | |||
| 2. Seed Round | 16-Dec-2016 | $376K | $376K | Completed | Startup | |
| 1. University Spin-Out | 12-Feb-2016 | Completed | Startup |
Mogrify Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Ordinary | ||||||||
| C Ordinary | ||||||||
| C Ordinary | ||||||||
| C Ordinary | ||||||||
| C Ordinary | ||||||||
| B Ordinary | ||||||||
| B Ordinary | ||||||||
| B Ordinary | ||||||||
| B Ordinary | 1,700 | $0.000013 | $19.02 | $19.02 | $19.02 | 0.12% | ||
| B Ordinary | 42,000 | $0.000013 | $3.62 | $3.62 | $3.62 | 3.06% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Mogrify Comparisons
Industry
Financing
Details
Mogrify Competitors (24)
One of Mogrify’s 24 competitors is Brainstorm Cell Therapeutics, a Corporation company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Brainstorm Cell Therapeutics | Corporation | New York, NY | ||||
| Asgard Therapeutics | Venture Capital-Backed | Lund, Sweden | ||||
| Sirnaomics | Formerly VC-backed | Gaithersburg, MD | ||||
| Orgenesis | Corporation | Germantown, MD | ||||
| Neurogene | Formerly VC-backed | New York, NY |
Mogrify Patents
Mogrify Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202415089-D0 | Cell conversion | Pending | 14-Oct-2024 | ||
| WO-2026083068-A1 | Cell conversion | Pending | 14-Oct-2024 | ||
| GB-202407725-D0 | Cell conversion | Inactive | 31-May-2024 | ||
| WO-2025248252-A1 | Cell conversion into cochlear hair cells | Pending | 31-May-2024 | ||
| EP-4508223-A1 | Cell conversion | Pending | 11-Apr-2022 | C07K14/4705 |
Mogrify Signals
Mogrify Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Meltwind Advisory | Venture Capital | Minority | ||
| Astellas Venture Management | Corporate Venture Capital | Minority | ||
| Trend Investment Group | Venture Capital | Minority |
Mogrify Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Chondrogenix | Cambridge, United Kingdom | 2017 |
Mogrify FAQs
-
When was Mogrify founded?
Mogrify was founded in 2016.
-
Where is Mogrify headquartered?
Mogrify is headquartered in Cambridge, United Kingdom.
-
What is the size of Mogrify?
Mogrify has 25 total employees.
-
What industry is Mogrify in?
Mogrify’s primary industry is Discovery Tools (Healthcare).
-
Is Mogrify a private or public company?
Mogrify is a Private company.
-
What is the current valuation of Mogrify?
The current valuation of Mogrify is .
-
What is Mogrify’s current revenue?
The current revenue for Mogrify is .
-
How much funding has Mogrify raised over time?
Mogrify has raised $49.9M.
-
Who are Mogrify’s investors?
, , Meltwind Advisory, Astellas Venture Management, and Trend Investment Group are 5 of 13 investors who have invested in Mogrify.
-
Who are Mogrify’s competitors?
Brainstorm Cell Therapeutics, Asgard Therapeutics, Sirnaomics, Orgenesis, and Neurogene are some of the 24 competitors of Mogrify.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process